Have a personal or library account? Click to login
Anti-inflammatory activity of novel natural plant extracts composition—LevidorTM Cover

Anti-inflammatory activity of novel natural plant extracts composition—LevidorTM

Postępy Higieny i Medycyny Doświadczalnej
Volume 77 (2023): Issue 1 (January 2023)
By: Monika Kuczyńska,  Paulina Kasprzyk,  Magdalena Leszczyńska-Wiloch,  Joanna Bidzińska,  Marcin Martyniak,  Alicja Wilandt and  Krzysztof Lemke  
Open Access
|May 2023

Figures & Tables

Fig. 1

The effect of LevidorTM extract on pro-inflammatory markers (IL-6, TNF-α) induced by LPS in the RAW267.7 cells. All results are given as means ± SD of three independent determinations. Negative control (C−) refers to cells treated with solvent, while positive control (C+) relates to cells treated with inflammatory inducer only. Significantly different values are marked as (*) p ≤ 0.05
The effect of LevidorTM extract on pro-inflammatory markers (IL-6, TNF-α) induced by LPS in the RAW267.7 cells. All results are given as means ± SD of three independent determinations. Negative control (C−) refers to cells treated with solvent, while positive control (C+) relates to cells treated with inflammatory inducer only. Significantly different values are marked as (*) p ≤ 0.05

Fig. 2

Changes in COX-1 (A) and COX-2 (B) gene expression in the U937 cells after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2,5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 2, 4, 6, and 16 h. Results are presented as fold changes in the expression of investigated genes. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer. Significantly different values are marked as (*) p ≤ 0.05. The results are calculated based on three independent experiments
Changes in COX-1 (A) and COX-2 (B) gene expression in the U937 cells after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2,5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 2, 4, 6, and 16 h. Results are presented as fold changes in the expression of investigated genes. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer. Significantly different values are marked as (*) p ≤ 0.05. The results are calculated based on three independent experiments

Fig. 3

Western blot analysis of the modulation of COX-1 and COX-2 protein abundance in the U937 after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2.5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 24 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)
Western blot analysis of the modulation of COX-1 and COX-2 protein abundance in the U937 after 48 h pre-treatment with PMA (10 ng/mL), followed by 40 h of incubation without treatment, 4 h treatment with 1, 2.5, 5, 10, 25, and 50 μg/mL of LevidorTM as well as LPS addition (1 μg/mL) for 24 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)

Fig. 4

Visualisation of COX-1 and COX-2 protein in the U937 cells after 24 h pre-treatment with PMA (10 ng/mL), followed by 24 h of incubation without treatment, 4 h treatment with 10, 25, and 50 μg/mL of LevidorTM as well as TNF-α addition (100 ng/mL) for 20 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)
Visualisation of COX-1 and COX-2 protein in the U937 cells after 24 h pre-treatment with PMA (10 ng/mL), followed by 24 h of incubation without treatment, 4 h treatment with 10, 25, and 50 μg/mL of LevidorTM as well as TNF-α addition (100 ng/mL) for 20 h. Negative control (C−) refers to cells treated with PMA, while positive control (C+) relates to cells treated also with inflammatory inducer (LPS)

Forward and reverse sequences of applied primers

GeneForwardReverse
GAPDH5′-AACGACCCCTTCATT-GAC-3′5′-TCCACGACATACTCAG-CA-3′
COX-15′-TCTCAGGCTA-CACCCTAGACCA-3′5′-ATCGGGGTAGTCCGAG-TAACGT-3′
COX-25′-CAGCACTTCACGCAT-CAGTT-3′5′-CGCAGTTTACGCTGTC-TAGC-3′

Values of IC50 obtained by MTT test

Cell lineIC50 [μg/mL]
RAW264.37not cytotoxic at concentration range tested
PC-12193.1
DOI: https://doi.org/10.2478/ahem-2023-0008 | Journal eISSN: 1732-2693
Journal RSS Feed
Language: English
Page range: 49 - 58
Submitted on: Oct 14, 2022
Accepted on: Mar 21, 2023
Published on: May 22, 2023
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
phytochemicals,
plant-based product,
anti-inflammatory,
cyclooxygenases
Related subjects:
Life sciences,
Molecular biology,
Microbiology and virology,
Medicine,
Basic medical science,
Immunology

© 2023 Monika Kuczyńska, Paulina Kasprzyk, Magdalena Leszczyńska-Wiloch, Joanna Bidzińska, Marcin Martyniak, Alicja Wilandt, Krzysztof Lemke, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 77 (2023): Issue 1 (January 2023)Next article